Basic information about inhibitors

IPAD-DB ID	C00833
Name	Ginsenoside Re
Category	Natural compounds
2D Structure
3D Structure
Molecular Formula	C 4 8 H 8 2 O 1 8
Molecular Weight	947.2 g/mol
IUPAC Name	(2S, 3R, 4R, 5R, 6S)-2-[(2R, 3R, 4S, 5S, 6R)-2-[[(3S, 5R, 6S, 8R, 9R, 10R, 12R, 13R, 14R, 17S)-3, 12-dihydroxy-4, 4, 8, 10, 14-pentamethyl-17-[(2S)-6-methyl-2-[(2S, 3R, 4S, 5S, 6R)-3, 4, 5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2, 3, 5, 6, 7, 9, 11, 12, 13, 15, 16, 17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-4, 5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-methyloxane-3, 4, 5-triol
InChI	InChI=1S/C48H82O18/c1-21(2)11-10-14-48(9, 66-42-38(60)35(57)32(54)26(19-49)63-42)23-12-16-46(7)30(23)24(51)17-28-45(6)15-13-29(52)44(4, 5)40(45)25(18-47(28, 46)8)62-43-39(36(58)33(55)27(20-50)64-43)65-41-37(59)34(56)31(53)22(3)61-41/h11, 22-43, 49-60H, 10, 12-20H2, 1-9H3/t22-, 23-, 24+, 25-, 26+, 27+, 28+, 29-, 30-, 31-, 32+, 33+, 34+, 35-, 36-, 37+, 38+, 39+, 40-, 41-, 42-, 43+, 45+, 46+, 47+, 48-/m0/s1
InChIKey	PWAOOJDMFUQOKB-WCZZMFLVSA-N
Canonical SMILES	CC1C(C(C(C(O1)OC2C(C(C(OC2OC3CC4(C(CC(C5C4(CCC5C(C)(CCC=C(C)C)OC6C(C(C(C(O6)CO)O)O)O)C)O)C7(C3C(C(CC7)O)(C)C)C)C)CO)O)O)O)O)O
PubChem CID	441921
DrugBank Accession Number	DB14815
CAS Registry Number	52286-59-6

Biological activity data

Ki	-
EC50	-
IC50	-
Inhibition	-
Toxicity	-
ROS(reactive oxygen species)	-
Metal Chelating	-
BBB(blood-brain barrier)	-
Target Protein	Aβ25-35
Effects	Protect SH-SY5Y cells against Aβ25-35-induced cytotoxicity, alleviate mitochondrial dysfunction and prevented the mitochondria-mediated apoptotic pathway in SH-SY5Y cells after Aβ25–35 exposure, inhibit Aβ-induced ASK-1/JNK activation in a ROS-dependent manner, attenuate Aβ-induced cellular oxidative stress by activating Nrf2-antioxidant signaling, alleviate Aβ-induced cytotoxicity and ROS generation in SH-SY5Y cells in a Nrf2-dependent manner
Research Models	In SH-SY5Y cells
Main Source	Ginseng
Ref. Link

Physicochemical properties

Molecular Weight(Computed by SwissADME)	947.15
Hac(Computed by SwissADME)	66
Volume(Computed by ADMETlab 2.0)	934.456
Density(Computed by ADMETlab 2.0)	1.013
nRing(Computed by ADMETlab 2.0)	7
MaxRing(Computed by ADMETlab 2.0)	17
nHet(Computed by ADMETlab 2.0)	18
fChar(Computed by ADMETlab 2.0)	0
nRig(Computed by ADMETlab 2.0)	39
Flexibility(Computed by ADMETlab 2.0)	0.308
Stero Centers(Computed by ADMETlab 2.0)	26
LogS(Computed by ADMETlab 2.0)	-2.874
LogD(Computed by ADMETlab 2.0)	2.088

ADMET properties

logP(Computed by ADMETlab 2.0)	1.448
TPSA(Computed by SwissADME)	298.14
Hbond Acceptor(Computed by SwissADME)	18
Hbond Donor(Computed by SwissADME)	12
Rotatable Bonds(Computed by SwissADME)

Pharmacokinetics

GI Absorption(Computed by SwissADME)	Low
BBB(blood-brain barrier) Permeant(Computed by SwissADME)	No
P-gp Substrate(Computed by SwissADME)	Yes
CYP1A2 Inhibitor(Computed by SwissADME)	No
CYP2C19 Inhibitor(Computed by SwissADME)	No
CYP2C9 Inhibitor(Computed by SwissADME)	No
CYP2D6 Inhibitor(Computed by SwissADME)	No
CYP3A4 Inhibitor(Computed by SwissADME)	No
log Kp(Skin Permeation)(Computed by SwissADME)	-10.96

Druglikeness

Lipinski(Computed by SwissADME)	3
Ghose(Computed by SwissADME)	3
Veber(Computed by SwissADME)	2
Egan(Computed by SwissADME)	1
Muegge(Computed by SwissADME)	4
Bioavailability Score(Computed by SwissADME)	0.17